Home ›
Thyroid Cancer Trials ›
NCT04290663
Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up
This trial is comparing two strategies in intermediate-risk differentiated thyroid cancer patients: Systematic radioiodine administration versus decision of radioiodine treatment guided by a post-operative work-up based on serum Tg values and diagnostic RAI scintigraphy
Trial Details
NCT ID NCT04290663
Phase PHASE3
Sponsor Centre Francois Baclesse
Status RECRUITING
Cancer Type Thyroid Cancer
Interventions Systematic RAI-treatment Decision of RAI-treatment guided by a post-operative assessment
Locations (sample) Pointe à Pitre, Guadeloupe, France|44.07984,1.98937 Angers, France|47.47156,-0.55202 Angers, France|47.47156,-0.55202 Bordeaux, France|44.84124,-0.58046 Bordeaux, France|44.84124,-0.58046
Key Eligibility Criteria
Subgroup of patients with differentiated thyroid cancer and intermediate-risk defined as follows according to TNM 2017: Papillary thyroid cancer (PTC) without aggressive subtype, follicular thyroid cancer (FTC) (with \< 4 foci of vascular invasion) or Hürthle cell ca… T1b or T2 with minimal extra-thyroid extension into the perithyroidal soft tissues and/or pN1 with largest nodal dimension between 2 and 10 mm, wit… T1aN1 with largest nodal dimension between 2 and 10 mm, without extra-capsular invasion and with a number of metastatic nodes ≤ 10
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Thyroid Cancer Trials on Trialify →